Pfizer vaccine 75% effective after first shot: Israeli study

A team of Israeli researchers showed that Covid-19 infections reduced by 75 per cent after the administration of the first dose of the Pfizer vaccine

Pfizer vaccine
Pfizer vaccine
IANS Jerusalem
2 min read Last Updated : Feb 19 2021 | 6:54 PM IST

A team of Israeli researchers on Friday showed that Covid-19 infections reduced by 75 per cent after the administration of the first dose of the Pfizer vaccine.

The data, published in the peer-reviewed Lancet medical journal, centered on a study of around 9,000 Sheba healthcare workers, around 7,000 of which received their first dose in January.

The researchers at Sheba Medical Center found a 75 per cent decrease in all infections and an 85 per cent reduction in symptomatic infections between 15-28 days after vaccination, The Jerusalem Post reported.

According to Gili Regev-Yochay, director of the hospital's Infectious Disease Epidemiology Unit, only 170 people became infected during the two week period. Of those who contracted the virus, 99 showed symptoms. Eighty-nine of the sick were unvaccinated.

She said the hospital is now completing research on the impact of the second dose, which she said researchers still believe is essential. However, she noted that the research supports the UK government's decision to spread out the time between the first and second shots of the vaccine in order to inoculate more people.

Regev-Yochay noted that there was at least one limitation on the data -- that hospital workers tend to be under the age of 65 and healthier than the rest of the population, so it is possible that less people got sick or showed symptoms for that reason.

--IANS

vc/arm

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Feb 19 2021 | 6:49 PM IST

Next Story